Millennium Inks Velcade Co-Promotion Deal With J&J In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreement provides for two-year co-promotion deal with J&J’s Ortho Biotech subsidiary.
You may also be interested in...
Millennium Earnings No Shocker, But How High Can Velcade Fly?
“In flux” myeloma space keeps analysts guessing.
Millennium Earnings No Shocker, But How High Can Velcade Fly?
“In flux” myeloma space keeps analysts guessing.
Velcade As Front-Line Multiple Myeloma Treatment Solidified By Phase III Data
Millennium plans to file an sNDA for the indication seeking a priority review by the first quarter of 2008.